Illumina, Inc. (NASDAQ:ILMN) Receives Average Recommendation of "Hold" from Brokerages

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) has received an average rating of "Hold" from the twenty-one research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $139.85.

A number of equities research analysts have weighed in on ILMN shares. Citigroup decreased their target price on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research report on Monday. Canaccord Genuity Group cut their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a research report on Tuesday, March 11th. Morgan Stanley lowered their price target on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 11th. Guggenheim reduced their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, Hsbc Global Res cut Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th.

Hedge Funds Weigh In On Illumina

Institutional investors have recently made changes to their positions in the stock. Golden State Wealth Management LLC acquired a new stake in Illumina during the fourth quarter worth approximately $32,000. Versant Capital Management Inc boosted its holdings in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after purchasing an additional 146 shares during the last quarter. Fourth Dimension Wealth LLC purchased a new stake in shares of Illumina in the fourth quarter valued at $40,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina in the fourth quarter valued at $45,000. Finally, Assetmark Inc. lifted its position in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after buying an additional 296 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Illumina Trading Up 8.5 %

NASDAQ:ILMN traded up $6.00 during mid-day trading on Friday, hitting $76.30. 4,431,316 shares of the stock traded hands, compared to its average volume of 2,253,515. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina has a 52 week low of $68.13 and a 52 week high of $156.66. The stock has a market capitalization of $12.09 billion, a price-to-earnings ratio of -9.93, a PEG ratio of 1.60 and a beta of 1.38. The firm's 50 day moving average is $90.77 and its two-hundred day moving average is $123.08.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities research analysts predict that Illumina will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.